ACIU - AC Immune SA Stock Trading

Seven presentations by AC Immune and its partners at AAT-AD/PD™ New data on early-stage TDP-43 and alpha-synuclein therapeutic and diagnostic candidates   A lead anti-alpha-synuclein therapeutic antibody candidate has advanced into preclinical development to treat P...

AC Immune (NASDAQ: ACIU ): FY Non-GAAP EPS of CHF0.64; GAAP EPS of CHF0.64 misses by CHF0.03 . More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more ...

Ongoing strong financial position with CHF 288.6 million in cash, ensuring the Company is fully financed through Q1 2024, excluding potential incoming milestones Received CHF 110 million in upfront and development milestone payments and a USD 50 million equity note in 2019 as a result o...